跳转至内容
Merck
CN

SML2268

Sigma-Aldrich

Micafungin sodium

≥97% (HPLC), powder, β(1,3)-D-Glucan synthase inhibitor

别名:

1-[(4R,5R)-4,5-Dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]pneumocandin A0 sodium salt

登录查看公司和协议定价

关于此项目

经验公式（希尔记法）:
C56H70N9O23S · Na
CAS Number:
208538-73-2
分子量:
1292.26
MDL编号:
MFCD08067752
UNSPSC代码:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Product Name

Micafungin sodium, ≥97% (HPLC)

方案

≥97% (HPLC)

表单

powder

储存条件

protect from light

颜色

white to beige

溶解性

H2O: 2 mg/mL, clear (warmed)

运输

wet ice

储存温度

−20°C

SMILES字符串

O=C(N[C@H]1C[C@@H](O)[C@@H](O)NC([C@@H]2[C@@H](O)[C@@H](C)CN2C([C@H]([C@H](O)CC(N)=O)NC([C@@H](NC([C@]3([H])C[C@@H](O)CN3C([C@H]([C@H](O)C)NC1=O)=O)=O)[C@H](O)[C@H](C4=CC(OS(=O)([O-])=O)=C(O)C=C4)O)=O)=O)=O)C5=CC=C(C6=NOC(C7=CC=C(OCCCCC)C=C7)=C6)C=C5.[Na+

InChI

1S/C56H71N9O23S.Na/c1-4-5-6-16-86-32-9-7-8-29(17-32)39-21-33(63-87-39)27-10-12-28(13-11-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-14-15-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76;/h7-15,17-18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,16,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85);/q;+1/p-1/t25?,26-,31-,34+,35+,37-,38-,42?,43+,44?,45+,46+,47+,48+,52?;/m1./s1

InChI key

DDVWCESGUGLBJI-OZMKZJPFSA-M

应用

Micafungin sodium has been used as an anti-fungal agent to test its effectiveness against multidrug-resistant C. auris by in vitro minimum inhibitory concentration (MIC) assay.

生化/生理作用

Micafungin is a semisynthetic echinocandin antifungal. Micafungin works by inhibiting the enzyme β(1,3)-D-Glucan synthase and thereby disturbing the integrity of the fungal cell wall. This enzyme does not exist in mammalian systems.
Micafungin is used for first-line treatment of invasive and esophageal candidiasis in addition to prophylaxis of Candida infections in both adults and children.
Semisynthetic echinocandin antifungal that inhibits 1,3-β-D-glucan synthase which is required for cell wall synthesis.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000424634
0000424634
0000387931
0000375416
0000375418

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

David Andes et al.
Antimicrobial agents and chemotherapy, 55(5), 2113-2121 (2011-02-09)
Echinocandins have become a first-line therapy for invasive candidiasis (IC). Using phase 3 trial data for patients with IC, pharmacokinetic-pharmacodynamic (PK-PD) relationships for efficacy for micafungin were examined. Micafungin exposures were estimated using a population pharmacokinetic model, and univariable and
Roeland E Wasmann et al.
Clinical pharmacokinetics, 57(3), 267-286 (2017-08-10)
Micafungin is a selective inhibitor of the synthesis of fungal 1,3-β-D-glucan, an essential component of the fungal cell wall. It is available as a powder for infusion only and is registered for the treatment of invasive and esophageal candidiasis in
David S Perlin
Future microbiology, 6(4), 441-457 (2011-04-30)
It has been nearly a decade since caspofungin was approved for clinical use as the first echinocandin class antifungal agent, followed by micafungin and anidulafungin. The echinocandin drugs target the fungal cell wall by inhibiting the synthesis of β-1,3-D-glucan, a
G Kofla et al.
European journal of medical research, 16(4), 159-166 (2011-04-14)
Echinocandins represent the newest class of antifungal agents. Currently, three echinocandins, anidulafungin, caspofungin and micafungin are licensed for clinical use in various indications. They act as inhibitors of β-(1,3)-glucan synthesis in the fungal cell wall and have a favorable pharmacological
Giardia hinders growth by disrupting nutrient metabolism independent of inflammatory enteropathy.
Giallourou, et al.
Nature Communications, 14, 2840-2840 (2023)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持